Global Sickle-cell Anemia Therapeutics Market: Overview
Anemia is a condition in which blood is unable to carry the optimum amount of oxygen due to severe reduction of RBC count or hemoglobin. Sickle cell disease is an inherited group of disorders in which red blood cells distort into a sickle shape. In the early stage of their life cycle, the cells die, thereby causing deficiency of healthy red blood cells. This condition is termed as sickle-cell anemia. This is accompanied by blockage of blood flow causing pain, a condition is termed as sickle cell crisis, along with microbial infections, swelling in the limbs, and sometimes, stroke. Chronic pain could develop with age. Treatments include blood transfusions, medication, and bone marrow transplant.
Global Sickle-cell Anemia Therapeutics Market: Drivers and Restraints
Globally, and especially in Africa, governments are taking initiatives to prevent and cure sickle-cell anemia. This, in turn, will encourage manufacturers to manufacture in large quantities to meet the unmet medical demand, thereby propelling the sickle-cell anemia therapeutics market. According to the report published by the World Health Organization (WHO), Africa has the highest prevalence of sickle-cell disease. The governing bodies of the WHO have taken initiatives to address the problem. This is likely to drive the global sickle-cell anemia therapeutics market. Demand for early detection and prevention of curable diseases, especially among the adults, is increasing. This is projected to be a key opportunity in the sickle-cell anemia therapeutics market as the percentage of the geriatric population is increasing rapidly. Moreover, demand for safe and efficient drugs is gaining momentum in the sickle-cell anemia therapeutics market. However, side effects associated with existing medications and therapies restrain the market.
Global Sickle-cell Anemia Therapeutics Market: Key Segments
The global sickle-cell anemia therapeutics market can be segmented based on medication and end-user. In terms of medication, the market can be divided into antibiotics, pain-relieving medications, and hydroxyurea. Based on end-user, the global sickle-cell anemia therapeutics market can be classified into private clinics, hospitals, and infusion centers.
The global sickle-cell anemia therapeutics market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global sickle-cell anemia therapeutics market, followed by Europe. According to the Centers for Disease Control and Prevention, around 100,000 people in the U.S. were affected by sickle-cell diseases (SCDs) in 2016. Sickle-cell diseases are common among African Americans. Around 1 in 13 babies of African American descent are born with sickle-cell diseases. Rise in prevalence of the disease drives demand for prevention and cure, which in turn fuels the growth of the sickle-cell anemia therapeutics market in North America. Middle East & Africa is anticipated to be the most lucrative market due to rise in the number of cases of sickle cell diseases. Asia Pacific is expected to be a significant sickle-cell anemia therapeutics market in the near future. Adoption of new techniques for treatment and growing awareness about sickle-cell anemia in countries such as India and China is expected to create a large opportunity for the players in Asia Pacific.
Global Sickle-cell Anemia Therapeutics Market: Key Players
Key players in the global sickle-cell anemia therapeutics market are Bristol-Myers Squibb, Baxter, Daiichi Sankyo, Bluebird Bio, Eli Lilly and Company, GlycoMimetics, HemaQuest Pharmaceuticals, Emmaus Medical, Mast Therapeutics, Merck Sharp & Dohme, Pfizer, and Selexys Pharmaceuticals.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.